Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dna X (SONM) Research & Development (2018 - 2025)

Dna X (SONM) has disclosed Research & Development for 8 consecutive years, with $181000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 74.69% year-over-year to $181000.0, compared with a TTM value of $15.2 million through Sep 2025, up 473.85%, and an annual FY2024 reading of $14.2 million, up 703.33% over the prior year.
  • Research & Development was $181000.0 for Q3 2025 at Dna X, down from $909000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $12.5 million in Q4 2024 and bottomed at -$135000.0 in Q3 2022.
  • Average Research & Development over 5 years is $2.5 million, with a median of $1.1 million recorded in 2022.
  • The sharpest move saw Research & Development plummeted 102.46% in 2022, then soared 1250.65% in 2024.
  • Year by year, Research & Development stood at $3.9 million in 2021, then plummeted by 68.5% to $1.2 million in 2022, then fell by 24.04% to $926000.0 in 2023, then skyrocketed by 1250.65% to $12.5 million in 2024, then plummeted by 98.55% to $181000.0 in 2025.
  • Business Quant data shows Research & Development for SONM at $181000.0 in Q3 2025, $909000.0 in Q2 2025, and $1.6 million in Q1 2025.